Merck immunotherapy Keytruda shows promise in multiple myeloma trial

(Reuters) - Merck & Co's immunotherapy Keytruda led to a high response rate for patients with the blood cancer multiple myeloma when added to standard therapy in a small, early stage trial, according to data presented on Monday.

http://ift.tt/1XVB5ZG

from Reuters: Health News
via animenewspro